Pharmaceutical company Galderma has released topline results from a randomised study evaluating its hyaluronic acid filler, Restylane Volyme, for moderate-to-severe temple hollowing.
The study, involving 162 patients in China, found that at six months, 94.4% of treated patients achieved at least a one-grade improvement in both temples, compared with 2% in the untreated group. Treating investigators reported that 91.3% of participants continued to show improvement in both temples at 12 months.
More than 84% of patients remained satisfied with the natural look and feel of their temples through month 12. The treatment was generally well tolerated, with no treatment-related serious adverse events or granulomas reported.
Galderma shared that the findings add to the clinical evidence for Restylane Volyme in temple hollowing and may inform future development of its injectable portfolio in China.
Bill Andriopoulos, head of global medical affairs, commented, “These findings underscore Galderma’s focus on generating evidence that addresses growing patient concerns, including temple hollowing associated in part with the rise in medication-driven weight loss. By demonstrating Restylane Volyme’s effectiveness in this indication in Chinese patients, these data also support the expansion of Restylane in a rapidly growing aesthetics market.”